EGFR and head and neck squamous cell carcinoma: Due to the limited improvement in the patient’s prognosis with traditional treatments, the epidermal growth factor receptor, tyrosine kinase inhibitors, and immune checkpoint inhibitors represented by cetuximab undoubtedly provide significant progress in the treatment of HNSCC when it comes to the clinical application [7,8].